Matrixx Initiatives (MTXX) Files Response with FDA on Zicam
More News related to MTXX
- Chesley Files Lawsuits on Behalf of Ohio Residents Who Lost Sense of Smell After Taking Zicam
- After-Hours Movers 1/25: THLD, VMW, MTXX, PLXT, PRXL Higher; ZRAN, CVO, ATHR, TXN, AAPL Lower
- Matrixx Initiatives (MTXX) reports Q3 EPS of $0.41, well ahead of the consensus of a $0.07 loss
- Matrixx Initiatives, Inc. Reports Fiscal 2010 Third Quarter Sales of $28.5 Million and Net Income of $3.8 Million
- Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2010 Financial Results
More News related to FDA
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
After months of informal discussions with the Federal Food and Drug Administration following their issuance of a warning letter on June 16, 2009 regarding the Company's nasal cold remedy products, the Matrixx Initiatives Inc. (Nasdaq: MTXX) filed its response on November 16.
Link to Letter
Related Categories
FDAMomentum Movers
Stocks Mentioned
+0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
